Advertisement
Research Article
Integrin αIIb (CD41) plays a role in the maintenance of hematopoietic stem cell activity in the mouse embryonic aorta
Jean-Charles Boisset, Thomas Clapes, Reinier Van Der Linden, Elaine Dzierzak, Catherine Robin
Biology Open 2013 2: 525-532; doi: 10.1242/bio.20133715

Summary

Integrins are transmembrane receptors that play important roles as modulators of cell behaviour through their adhesion properties and the initiation of signaling cascades. The αIIb integrin subunit (CD41) is one of the first cell surface markers indicative of hematopoietic commitment. αIIb pairs exclusively with β3 to form the αIIbβ3 integrin. β3 (CD61) also pairs with αv (CD51) to form the αvβ3 integrin. The expression and putative role of these integrins during mouse hematopoietic development is as yet unknown. We show here that hematopoietic stem cells (HSCs) differentially express αIIbβ3 and αvβ3 integrins throughout development. Whereas the first HSCs generated in the aorta at mid-gestation express both integrins, HSCs from the placenta only express αvβ3, and most fetal liver HSCs do not express either integrin. By using αIIb deficient embryos, we show that αIIb is not only a reliable HSC marker but it also plays an important and specific function in maintaining the HSC activity in the mouse embryonic aorta.

Introduction

Hematopoietic stem cells (HSCs) are at the foundation of the blood system and are the key cell type in transplantation protocols for blood-related disorders. The number of HSCs available for clinical applications and fundamental research is limited. The efficient expansion and/or generation in vitro is thus far not possible because our knowledge of the mechanisms underlying HSC growth, including the specific in vivo interactions between HSCs and the surrounding microenvironment are poorly understood.

Adult HSCs are generated only during a short window of developmental time (Boisset and Robin, 2012). They are first detected at embryonic day (E)10.5 of mouse development in the Aorta–Gonad–Mesonephros (AGM) region (Medvinsky and Dzierzak, 1996; Müller et al., 1994). Starting at E11, HSCs are also found in the yolk sac (YS), placenta (PL) and fetal liver (FL). The pool of HSCs expands in the PL and FL before colonizing the bone marrow (BM) from E17 onward (Gekas et al., 2005; Ottersbach and Dzierzak, 2005). Studies performed in the zebrafish, chicken and mouse models have clearly demonstrated that HSCs originate from specialized endothelial cells referred as hemogenic (Boisset and Robin, 2012). HSCs most likely reside in clusters of cells (Intra-Aortic Hematopoietic Clusters, IAHCs) that are tightly attached to the endothelium of the aorta, the vitelline and umbilical arteries, and the vascular labyrinth of the placenta (Rhodes et al., 2008; Yokomizo and Dzierzak, 2010). In adult BM, HSCs localize in specialized niches that maintain the balance between HSC self-renewal, quiescence and differentiation. Adhesion molecules (including integrins) are important for the binding of HSCs to the BM niches (Grassinger et al., 2009; Notta et al., 2011; Potocnik et al., 2000; Qian et al., 2006; Umemoto et al., 2006; Wagers and Weissman, 2006). In contrast to adult, the specific interactions and cell adhesion properties of HSCs in the aorta and the successive developmental niches are as yet poorly described.

Integrins are transmembrane glycoproteins (gp) that play an important role in cell adhesion, survival, proliferation, differentiation, migration, gene regulation, and cytoskeletal arrangement. They are a family of 24 heterodimeric receptors composed of α (18 types) and β (8 types) subunits (Prowse et al., 2011). While some integrins are ubiquitously expressed, others are tissue- or cell lineage-specific (Bouvard et al., 2001). Adult HSCs express several integrins important for homing and migration (e.g. α4β1, α5β1, α6β1) (Bonig et al., 2009a; Bonig et al., 2009b; Grassinger et al., 2009; Lapidot et al., 2005). In the embryo, αIIb (platelet (gp)IIb or CD41) is one of the earliest surface markers of hematopoietic commitment (Emambokus and Frampton, 2003; Ferkowicz et al., 2003; McKinney-Freeman et al., 2009; Mikkola et al., 2003; Mitjavila-Garcia et al., 2002; Robin et al., 2011) and its expression is developmentally regulated. E11 AGM HSCs express αIIb, whereas HSCs in the E12 AGM, E12 PL or E14 FL are αIIb negative (Matsubara et al., 2005; McKinney-Freeman et al., 2009; Robin et al., 2011). By performing time-lapse confocal imaging on live mouse embryo slices, we have shown that the onset of αIIb expression coincides with the formation of hematopoietic stem/progenitor cells (HSPCs) from the hemogenic aortic endothelium (Boisset et al., 2011; Boisset et al., 2010) and that αIIb protein localizes at the point of contact between the cells in IAHCs.

To date little is known about integrin function and expression in HSCs throughout development. The BM of αIIb deficient mice show no hematopoietic lineage commitment problems (Tronik-Le Roux et al., 2000) but possess defective platelets and display bleeding disorders similar to those seen in β3 deficient mice (Hodivala-Dilke et al., 1999) and humans with Glanzmann thrombasthenia disease. Here we examine the expression of αIIb, β3 and αv integrin subunits on HSCs in the main hematopoietic sites (AGM, YS, PL, and FL) and the function of αIIb in these cells. αIIb exclusively associates with β3 to form the major platelet integrin αIIbβ3 (gpIIb/IIIa or CD41/CD61). β3 also associates with αv to form the αvβ3 integrin (CD51/CD61). We show by performing in vivo transplantation assays of sorted populations that newly generated E11 AGM HSCs express αIIbβ3 integrins whereas HSCs from E12 PL and E14 FL do not. αvβ3 is expressed on all AGM and PL HSCs but on only a few E14 FL HSCs. All three types of HSCs were found in the E12 YS. Interestingly, αIIb deficient embryos show an HSC defect in the AGM but not in the YS and FL, indicating that αIIb plays a fundamental and precise spatio-temporal role to maintain the HSC activity in the aorta of the mouse embryo.

Materials and Methods

Mice and embryo generation

Embryos were generated from crosses of hβ-globin ln72 mice and wild-type (C57BL/10×CBA)F1 females; Ly5.1 males and females; αIIb+/tk males and αIIb+/+ or αIIb+/tk females; αIIbtk/tk males and αIIb+/+ or αIIb+/tk females; wild-type C57BL/6 females and males. The day of vaginal plug observation is embryonic day (E)0. ln72, YMT and αIIb genotypes were determined by DNA PCR. Mice were housed according to institutional guidelines and all animal procedures were carried out in compliance with the Standards for human care and use of laboratory animals.

Dissections and cell preparation

E11–E14 embryos were isolated. Tissues (AGM, FL, YS, PL) were dissected and dissociated as previously described (Robin and Dzierzak, 2005). Viable cells were counted (using trypan blue) and kept in phosphate-buffered saline (PBS), 10% fetal calf serum, and penicillin/streptomycin (PBS/FCS/PS) at 4°C for further analysis.

Explant culture

Whole AGMs were cultured as explants at 37°C for 3 days as previously described (Medvinsky and Dzierzak, 1996). Explant cultures of αIIb mutant AGMs were performed with no added cytokines. To test the number of CD41intCD61intCD45intc-kit+ cells per wild-type AGM, the medium was supplemented or not with 200 ng/ml of recombinant murine IL-3 (Robin et al., 2006) or 250 ng/ml of gremlin (Durand et al., 2007).

Hematopoietic progenitor assay

In vitro hematopoietic progenitor analysis was performed on dilutions of sorted cells plated in triplicates in methylcellulose medium (StemCell Technologies). Plates were incubated at 37°C in a humidified chamber under 5% CO2. Hematopoietic colonies were counted with an inverted microscope at day 12 of the culture.

In vivo transplantation assay and transplanted mice analysis

Intravenous injection of total or sorted cells into irradiated adult wild-type recipients was as previously described (Robin et al., 2006). Recipient female mice ((129/SV×C57BL/6), C57BL/6 or (CBA×C57BL/10)) were exposed to a split dose of 9 Gy of γ-irradiation (137Cs source) and injected with several cell doses (or embryo equivalent, ee). 2×105 spleen cells (recipient background) were co-injected to promote short-term survival.

Blood was obtained at 1 and 4 months post-transplantation and DNA was analyzed for donor cell markers by semiquantitative PCR (hβ-globin, αIIb, Ymt). The percentage of donor contribution was calculated from a standard curve of DNA control dilutions (0 to 100% donor marker). Recipients were considered repopulated when the chimerism was greater than 10%. For multilineage repopulation analysis, thymus, lymph nodes, bone marrow and spleen were dissected from the repopulated recipients. T, B, erythroid, and myeloid cells were sorted from recipient BM and spleens after antibody staining (see below). Primary recipient BM cells were injected into secondary irradiated recipients to assess self-renewal capacity (0.5×106 or 2×106 cells injected per recipient; supplementary material Fig. S4D). Chimerism level of the Ly5.2 recipients (C57BL/6) injected with Ly5.1 cells was determined by flow cytometry (see below). Recipients were considered repopulated when the chimerism was greater than 5%.

For statistical analysis, student's t test (Mann–Whitney) was used to determined statistical significance.

Flow cytometric analysis and sorting

Flow cytometric analysis and sorting were performed on a FACScan and/or AriaIII (BD Bioscience) with CellQuest and FACSDiva. Stainings were performed in PBS/FCS/PS for 30 min at 4°C. Cells were washed and resuspended in PBS/FCS/PS and 7-AAD (Molecular Probes, Leiden, NL) or Hoechst 33258 (1 µg/ml, Molecular Probes) for dead cell exclusion. The positive gates were defined from staining with isotype-matched control antibodies. Monoclonal antibodies (BD Pharmingen, eBioscience, Invitrogen, Santa Cruz, Biolegends) used: FITC-anti-Ter119, FITC-anti-CD42c (Gp1bβ); PE-anti-CD41; APC-anti-CD61; FITC, APC-Cy7 or APC-AlexaFluor750-anti-c-kit; FITC, PE or PE-Cy7-anti-CD31; PerCP-Cy5.5-anti-CD45; APC or Pacific Blue-anti-CD34; Alexa-Fluor488-anti-CD51; Lin cocktail (PE-anti-Ter119, PE-anti-B220, PE-anti-Mac1, PE-anti-Gr1, PE-anti-CD3ε); PE-anti-CD48; APC-anti-CD150 and PE-Cy7-anti-Sca-1.

Ly5.2/Ly5.1 cell chimerism was determined by flow cytometry on blood after erythrocyte lysis (Beckman Coulter) and staining with FITC-anti-Ly5.2, PE-anti-Ly5.1 and 7-AAD. Flow cytometry data were analyzed with FlowJo.

For multilineage repopulation analysis, spleen cells were stained with FITC-anti-B220, PE-anti-CD8a and PE-anti-CD4; bone marrow cells were stained with FITC-anti-Ly6C and PE-anti-CD31.

Cell cycle analysis

Cells from dissociated E11 AGM were stained with PE-anti-c-kit antibody. Cells were washed prior to fixation with 2% PFA for 30 min. Cells were then permeabilized for 1 h in 0.2% Triton X-100. After washing, cells were incubated during 1 h with FITC-anti-Ki-67 antibody or IgG isotype control. Cells were washed and incubated with Hoechst 33342 (1 µg/ml, Molecular Probes) prior to analysis by flow cytometry.

Pre-apoptosis analysis

Cells from dissociated E11 AGM were stained with PE-anti-c-kit antibody. Cells were washed in cold PBS and resuspended in 1× binding buffer (10 mM Hepes/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) and stained for 20 min with Annexin-V-FITC and Hoechst 33258 (1 µg/ml, Molecular Probes). Analyses were performed within 1 h by flow cytometry.

Whole-mount immunostaining

The whole-mount immunostaining was performed as previously described (Yokomizo and Dzierzak, 2010). Rat anti-mouse primary antibodies for c-Kit (2B8) and biotinylated anti-CD31 (MEC13.3) were used (BD Biosciences). Secondary antibodies were goat anti-rat IgG-Alexa647 (Invitrogen) and streptavidin-Alexa594 (Invitrogen). Embryo caudal halves were imaged using a Leica SP5 confocal microscope.

Staining and confocal microscopy of non-fixed embryo and placenta slices

Non-fixed wild-type embryos were cut into thick transversal slices (200 µm) and stained with directly conjugated monoclonal antibodies as previously described (Boisset et al., 2011; Boisset et al., 2010). The antibodies include: PE-anti-CD41 (MWreg30), Alexa488-anti-CD51 (RMV-7), APC-anti-CD61. Similarly, placentas isolated from E12 non-fixed wild-type embryos were cut into slices (200 µm) and were incubated with PE-anti-Tie-2, Alexa488-anti-CD51 (RMV-7) and APC-anti-CD61. Slices were immobilized into agarose gel and imaged by using a Leica SP5 confocal microscope.

Results

Hematopoietic stem cells differentially express αIIbβ3 and αvβ3 integrins throughout development

HSCs are restricted to the CD41intermediate (CD41int) fraction in E11 AGM (McKinney-Freeman et al., 2009; Robin et al., 2011). However, HSCs in E12 AGM and PL, and E14 FL are exclusively in the CD41− fraction. In YS, HSCs are in both populations (Robin et al., 2011). To further investigate integrin subunit expression on HSCs, we performed flow cytometric analyses for αv (CD51) and β3 (CD61), in addition to αIIb (CD41) expression. Cells were analysed at the time points corresponding to organ-specific peaks of HSC activity and subunit expression was found to differ between tissues (Fig. 1). CD41intCD61− cells were found only in E11 AGM (Fig. 1A), and not in E12 YS (Fig. 1C), E12 PL (Fig. 1E) or E14 FL (Fig. 1G). CD41−CD61high cells were found mainly in E12 PL (Fig. 1E) and to a lesser extent in E11 AGM (Fig. 1A). Three distinct cell populations were present in all tissues: CD41−CD61−, CD41−CD61int and CD41intCD61int.

Fig. 1.
Fig. 1. Phenotypic and functional analyses of integrin-based sorted cell fractions.

(A,C,E,G) Flow cytometric analyses of E11 Aorta–Gonad–Mesonephros (AGM), E12 yolk sac (YS), E12 placenta (PL) and E14 fetal liver (FL). Representative sorting gates of each population are indicated. (B,D,F,H) Hematopoietic repopulation analyses after injection of integrin-based sorted fractions of AGM (n = 2), YS (n = 4), PL (n = 2) and FL (n = 3). Numbers above columns indicate number of mice repopulated/number of mice injected. Dose of injected cells is indicated as embryo equivalent (ee).

To determine whether HSCs in E11 AGM expressed both αIIb and β3 subunits, CD41intCD61− and CD41intCD61int fractions were sorted and injected into adult wild-type irradiated recipients (n = 2 (n = independent experiments when not specified otherwise)). Four months post-transplantation, the mice injected with CD41intCD61int cells were reconstituted (5 mice reconstituted out of 6 mice transplanted, 5/6). No mice (0/8) injected with CD41intCD61− cells were reconstituted, even with a high cell dose (3 ee per mouse) (Fig. 1B). High-level multilineage engraftment of blood, BM, spleen, lymph nodes and thymus was found in the recipients receiving CD41intCD61int cells (supplementary material Fig. S1, top panel) and secondary recipients were successfully engrafted with BM from these primary recipients, thus demonstrating that the CD41intCD61int population contains bona fide HSCs (supplementary material Fig. S1, bottom panel). 95% of the CD41intCD61int cells also expressed CD51 (Table 1). At E12, AGM HSCs were CD41− (Robin et al., 2011) but still expressed CD51 (Table 1). Thus, all HSCs in E11 AGM express both αIIbβ3 and αvβ3 integrins.

View this table:
Table 1. Percentage of CD51+ cells in the cell fractions enriched in hematopoietic stem cells.

YS HSCs are both CD41− and CD41int at E11 and E12 (Robin et al., 2011). In combination with CD61, three cell fractions were sorted from E12 YS (CD41−CD61−, CD41−CD61int and CD41intCD61int) (Fig. 1C) and transplanted (n = 4). Multilineage engraftment was obtained with all fractions (Fig. 1D). Similar to E11 AGM HSCs, YS cells in the CD41intCD61int and CD41−CD61int fractions expressed CD51 (97% and 72% respectively) (Table 1). On the other hand, the majority of CD41−CD61− cells did not express CD51 (Table 1). Thus, YS and AGM contain HSCs that express both αIIbβ3 and αvβ3 integrins, whereas some YS HSCs express solely αvβ3 integrin or none of these integrins.

HSCs in PL and FL are CD41− (Robin et al., 2011). CD41−CD61−, CD41−CD61int and CD41−CD61high (only present in PL) fractions were sorted (Fig. 1E,G) and transplanted (PL: n = 2, FL: n = 3). The PL CD41−CD61int fraction (but not the CD41−CD61− fraction) contained HSCs (Fig. 1F). Most of CD41−CD61int cells expressed CD51 (86%) (Table 1). Thus, CD41−CD61int HSCs in PL express only αvβ3 integrin and therefore resemble CD41−CD61int YS HSCs. In E14 FL, HSCs were in both CD41−CD61− and CD41−CD61int fractions (Fig. 1H). Limiting cell dilution transplantations (0.001 to 0.1 ee) showed that HSCs were enriched in the CD41−CD61− fraction (Fig. 1H). Similar to E12 PL and YS, CD41−CD61int FL cells also expressed CD51 (98%) (Table 1). In contrast, CD41−CD61− FL cells did not express CD51 (Table 1). Thus, all HSCs in the PL express αvβ3 but not αIIbβ3 integrins, whereas most FL HSCs do not express these integrins.

E11 AGM hematopoietic stem cells are enriched in the CD41intCD61intCD45intc-kit+ subpopulation

Further enrichment of the E11 AGM CD41intCD61int population was attempted with the pan-hematopoietic marker CD45 and the HSC marker c-kit (Sánchez et al., 1996). All committed cells from erythroid (Ter119+) and megakaryocytic (Gp1bβ+) lineages were first excluded (supplementary material Fig. S2A, left panel) and the CD41intCD61int HSC containing fraction (Fig. 1A,B) was sorted into four subfractions: CD45−c-kit−, CD45−c-kit+, CD45intc-kit+ and CD45highc-kit+ (supplementary material Fig. S2A, middle and right panels). Cells were injected into irradiated adult recipients and engraftment was measured at 1 month (short-term repopulation, STR) and 4 months (long-term repopulation, LTR) post-transplantation (n = 8). As expected, the CD45−c-kit− and CD45−c-kit+ subfractions yielded no repopulation, even with high doses of injected cells (5–10 ee) (supplementary material Fig. S2C). The CD45intc-kit+ and CD45highc-kit+ subfractions yielded short-term repopulation (supplementary material Fig. S2C, left panel), but only the CD45intc-kit+ subfraction was capable of long-term repopulation (supplementary material Fig. S2C, right panel). These cells provided high-level multilineage reconstitution of the primary and secondary transplanted recipients (supplementary material Fig. S2B). Thus, the CD41intCD61int population contains both STR-HSCs and LTR-HSCs that both express CD45 and c-kit. However, STR-HSCs and LTR-HSCs can be discriminated based on the level of CD45 expression: STR-HSCs are CD45high while LTR-HSCs are CD45int. There is as few as 96±31 CD41intCD61intCD45intc-kit+ cells per E11 AGM (n = 6). Thus, the combination of integrin expression with other hematopoietic markers such as CD45 and c-kit can be used to discriminate cell populations highly enriched in STR-HSCs and LTR-HSCs in E11 AGM.

Interestingly, the number of CD41intCD61intCD45intc-kit+ cells per AGM was increased when E11 AGM explants were cultured in the presence of IL-3 and decreased in the presence of Gremlin, as compared to non-supplemented controls (supplementary material Fig. S2D,E). This is consistent with our previous findings that IL-3 is a powerful amplifying factor (Robin et al., 2006) and Gremlin (a BMP antagonist) is an inhibitory factor for HSC activity in E11 AGM (Durand et al., 2007; Robin and Durand, 2010). Therefore, the refined CD41intCD61intCD45intc-kit+ HSC phenotype provides a rapid readout for testing the effects of specific molecules/reagents in AGM and perhaps other embryonic culture systems.

Localization of αIIb, αv and/or β3 integrin subunits expressing cells in the AGM and placenta

To determine the precise location of cells expressing αIIb, αv and/or β3, multicolour stainings were performed using the technique that we previously developed to stain non-fixed embryo slices (Boisset et al., 2011). We observed CD41intCD51intCD61int cells in the IAHCs of E10.5 embryos (Fig. 2A). Interestingly, the integrin subunits were concentrated at the junction between the IAHC cells.

Fig. 2.
Fig. 2. Location of phenotypically defined HSCs in AGM and placenta.

(A) Intra-aortic hematopoietic clusters (IAHCs) of E10.5 wild-type embryos. Non-fixed embryo slices were stained with antibodies against CD51 (αv), CD41 (αIIb) and CD61 (β3). Scale bars: 10 µm. (B) Non-fixed placenta slices (E12) were stained with antibodies against Tie-2. Transmitted light and fluorescent images are merged. Scale bar: 100 µm. (C) Confocal stack image of an E12 non-fixed placenta slice stained with antibodies against CD51, CD61 and Tie-2. Close up of the boxed area (left panel) shows a group of labelled cells (single and merged fluorescent channels are shown). Scale bars: 10 µm. UA: umbilical artery, C: chorionic plate, L: labyrinth, S: spongiotrophoblast layer, FV: fetal vessel.

The embryo slice staining technique was adapted to non-fixed PL. E12 PL slices stained with directly labelled anti-Tie-2 antibodies (Fig. 2B) showed specific staining of both placental vessels and umbilical artery (UA). This allowed discrimination of the chorionic plate (C), the vascular labyrinth (L) and the spongiotrophoblast layer (S) (Fig. 2B). To localize phenotypically defined HSCs in the Tie-2+ placental vessels (FV), multicolour staining was performed with anti-CD51 and CD61 antibodies (Fig. 2C). Groups of CD51intCD61int cells were observed in the vasculature of the chorionic plate and similar to the aorta, the integrin subunits were concentrated at the junctions between cells (Fig. 2C). Thus, integrin expressing HSCs are localized in the IAHCs as well as in the vasculature of the placental chorionic plate.

αIIb deficient embryos have no qualitative or quantitative defects in AGM hematopoietic progenitors or IAHCs

All hematopoietic progenitors are CD41int in the E11 AGM (Robin et al., 2011). To test whether αIIb plays a role in the production of hematopoietic progenitors, AGM cells from E11 wild-type (αIIb+/+) and αIIb mutant (αIIb+/tk and αIIbtk/tk) embryos (Tronik-Le Roux et al., 2000) were isolated and tested in the colony forming unit-culture assay (CFU-C; n = 3). As shown in Fig. 3A, AGMs of E11 mutant embryos contained erythroid and myeloid progenitors. The numbers of total CFU-C and of each type of progenitor were similar in the mutants as compared to wild-type AGMs, demonstrating that αIIb does not influence the production or function of AGM progenitors.

Fig. 3.
Fig. 3. Intra-aortic hematopoietic clusters and in vitro clonogenic progenitor activity of AGM cells isolated from E11 CD41 (αIIb) deficient embryos.

(A) In vitro clonogenic analyses. AGMs were isolated from E11 wild-type (αIIb+/+), heterozygous (αIIb+/tk) or homozygous deficient embryos (αIIbtk/tk). Error bars: standard deviations for n = 3 independent experiments. CFU-GEMM: CFU-Granulocyte–Erythroid–Macrophage–Megakaryocyte; CFU-GM: CFU-Granulocyte–Macrophage; CFU-M: CFU-Macrophage; CFU-G: CFU-Granulocyte; BFU-E: Burst-Forming Unit-Erythroid. (B) Number of c-kit+ cells per E11 αIIb+/+ (n = 5 embryos), αIIb+/tk (n = 5 embryos) and αIIbtk/tk (n = 3 embryos) aorta. Error bars: standard deviations. Confocal stack images of the mouse aorta region of E11 αIIb+/+ (C) and αIIbtk/tk (D) embryos after whole mount staining for c-kit and CD31. Scale bars: 50 µm. ns: not statistically significant. Error bars: standard deviations.

Whole embryo imaging of αIIb+/+, αIIb+/tk and αIIbtk/tk E11 embryos immunostained for CD31 (to visualize endothelial and IAHC cells) and c-kit (to visualize IAHC cells) revealed no differences in IAHC cell number (Fig. 3B), organization or shape (Fig. 3C,D). To investigate whether the lack of αIIb affects the expression of αv (CD51) and β3 (CD61), we performed flow cytometric analysis on αIIb+/+, αIIb+/tk and αIIbtk/tk E11 AGMs (supplementary material Fig. S3). CD51 and CD61 expression levels were similar between the different phenotypes, although the CD51+CD61high population was absent in the αIIbtk/tk AGMs. Thus, the absence of CD41 does not influence expression of CD51 and CD61. Together, these results show that αIIb is not needed for the formation, organization and anchorage of IAHCs, or there is functional redundancy with other integrins/adhesion molecules (e.g. αvβ3).

αIIb deficient embryos have a hematopoietic stem cell defect in the AGM

To test whether αIIb plays a role in the function of AGM HSCs, transplantations were performed with cells isolated from E11 wild-type (αIIb+/+) and αIIb mutant (αIIb+/tk and αIIbtk/tk) AGMs (n = 3). Whereas 72% of the mice injected with αIIb+/+ cells were reconstituted, only 29% and 38% of mice were reconstituted with αIIb+/tk or αIIbtk/tk cells, respectively, at four months post-transplantation (Fig. 4A). The percentage of donor cell chimerism was significantly lower in the few mice repopulated with αIIb+/tk or αIIbtk/tk cells (10% average) as compared to the mice injected with αIIb+/+ cells (60% average) (Fig. 4A, red bars). The reconstitution with αIIbtk/tk cells resulted in multilineage engraftment (supplementary material Fig. S4B,C) similar to that found in mice reconstituted with αIIb+/+ cells (supplementary material Fig. S4A). Secondary transplantations of BM cells (two cell doses, supplementary material Fig. S4D,E) isolated from two primary recipients repopulated with αIIbtk/tk AGM HSCs and one recipient repopulated with αIIb+/+ cells (Fig. 4A, red lozenges; supplementary material Fig. S4A,B,C) showed that αIIbtk/tk AGM HSCs were self-renewing. αIIbtk/tk AGM-derived cells successfully repopulated secondary recipients with similar chimerism as αIIb+/+ AGM-derived cells (supplementary material Fig. S4D,E). Thus, although αIIb+/tk and αIIbtk/tk embryos have fewer HSCs in the AGM as compared to αIIb+/+ embryos, these are fully functional HSCs.

Fig. 4.
Fig. 4. Functional analyses of AGM, yolk sac and fetal liver cells isolated from E11 CD41 (αIIb) deficient embryos.

Hematopoietic repopulation analysis of mice after injection of (A,B) AGM, (C) yolk sac or (D) fetal liver cells isolated from E11 wild-type (αIIb+/+), heterozygous (αIIb+/tk) or homozygous deficient embryos (αIIbtk/tk). (A,B) Percentage of chimerism in peripheral blood for each injected mice. Lozenge: one transplanted mouse. Red lozenge: mice used to perform secondary transplantations. Dashed line: limit of positivity (>10% of chimerism). Red line: chimerism average. (A) AGM cells were injected directly (n = 3) or (B) after explant culture (n = 3). The genotype of embryos, the number of mice repopulated/number of mice transplanted (# Rep./# Inj.) and the percentage of repopulated mice (% Rep.) are indicated below the graphs. 1 embryo equivalent (ee) of AGM cells was injected per recipient (n = 3). p-values are indicated. (C,D) Percentage of repopulated mice. Numbers below columns: number of mice repopulated/number of mice transplanted. (C) 1 ee of yolk sac cells (n = 3) and (D) 3 to 4.5 ee of fetal liver cells (n = 4) were injected per recipient. Due to the very low number of HSCs in E11 FL, αIIb+/tk and αIIbtk/tk cells were pooled. ns: not statistically significant.

It was previously shown that the number of HSCs increases when AGMs are cultured as explants for 3 days (Medvinsky and Dzierzak, 1996). We tested whether αIIb deficient HSCs can be maintained and expanded in AGM explant cultures (n = 3). Cells from αIIb+/tk or αIIbtk/tk AGM explants were able to reconstitute 13% and 20% of the transplanted recipients, as compared to 100% of recipients transplanted with cells from αIIb+/+ AGM explants (Fig. 4B). As expected the HSC repopulation ability of the αIIb+/+ AGM cells was higher after explant culture, as compared to transplantations performed without pre-culture (Fig. 4A). In contrast the HSC repopulation ability of the αIIb mutant AGM cells was significantly lower. This was not due to abnormal cycling or increased apoptosis of c-kit+ cells in the αIIb mutant AGM (supplementary material Fig. S5A,B, respectively). Altogether, the results support a role for αIIb in the maintenance of AGM HSC repopulating activity.

αIIb deficient embryos have no major hematopoietic stem cell defect in the YS or FL

HSC activity of αIIb mutant YSs was also tested (only some YS HSCs express αIIb). Transplantations with YS cells isolated from E11 αIIb+/+, αIIb+/tk and αIIbtk/tk embryos (n = 3) showed similar percentages of mice reconstituted (28%, 22% and 20%, respectively) at four months post-transplantation (Fig. 4C). Thus, while there is a strong HSC defect in the AGM of the αIIb mutant embryos, it is not the case in the YS.

Similarly, we performed transplantations with FL cells isolated from E11 αIIb+/+, αIIb+/tk and αIIbtk/tk embryos (n = 4), at the time when HSCs start to colonize the FL. The percentage of reconstituted mice after the injection of αIIb+/tk or αIIbtk/tk cells (25%) was similar to the percentage of reconstituted mice after the injection of αIIb+/+ cells (14%) (Fig. 4D) thus showing that αIIb mutant HSCs are able to migrate and colonize the FL in vivo.

We further tested the HSC activity in the FL of αIIb mutant embryos at E14, a time point when HSCs extensively expand. Flow cytometry for Lin−Sca-1+c-kit+CD48−CD150+ cells showed that the absolute numbers of these phenotypically defined HSCs were similar in αIIb mutant embryos as compared to wild type (supplementary material Fig. S6). Limiting dilution transplantation of FL cells (0.001 [n = 3] and 0.005 [n = 3] ee per recipient) (Fig. 5) showed that αIIb mutant FL cells were as competent as αIIb+/+ FL cells in recipient reconstitution. Thus, HSCs have no proliferative defect in the FL of the αIIb mutant embryos.

Fig. 5.
Fig. 5. Functional analyses of E14 fetal liver cells isolated from CD41 (αIIb) deficient embryos.

Hematopoietic repopulation analysis of mice after the injection of fetal liver cells isolated from E14 wild-type (αIIb+/+; grey bars), heterozygous (αIIb+/tk; dark grey bars), or homozygous deficient (αIIbtk/tk; black bars embryos. Numbers above columns: number of mice repopulated/number of mice transplanted.

Discussion

The αIIb integrin subunit (CD41) is one of the first surface markers indicative of hematopoietic commitment (Ferkowicz et al., 2003; McKinney-Freeman et al., 2009; Mikkola et al., 2003; Robin et al., 2011). It is notably expressed by the first hematopoietic cells emerging from the hemogenic endothelium in the aorta (Boisset et al., 2010). We found here that αIIb is not only a reliable HSC marker, but it also plays an important role in maintaining HSC activity in the aorta.

We have also found that HSCs differentially express αIIb, β3 and αv integrin subunits during ontogeny. Since HSCs in embryos are difficult to identify in situ, integrin expression can be used in combination with other markers (as CD45 and c-kit) to enrich and localize HSCs throughout development. Surprisingly, a substantial fraction of HSCs in the E11/E12 YS do not express αIIb and/or β3 integrin subunits. Such HSCs are not detectable in the AGM at the same time point, the YS might generate such a subset of HSCs. The results of in vivo CD41-Cre-mediated genetic tagging suggest that all/most HSCs go through an αIIb expressing phase, as is reflected by a high percentage of labelled hematopoietic cells in the adult animals (35–65%) (Rybtsov et al., 2011). Thus, the expression of integrins on the surface of HSCs appears to not only be regulated developmentally, but also by the surrounding cells that compose the HSC niches.

IAHC cells express αIIb (Corbel and Salaün, 2002; Yokomizo and Dzierzak, 2010). Due to low expression levels, the visualization of CD41 by immunostaining embryo cryosections is rather difficult and often is in the context of high background. However, our results show that immunostaining of non-fixed embryo slices with directly conjugated antibodies allows the visualization of low level of integrin expression in the aorta with good resolution (Boisset et al., 2011; Boisset et al., 2010). We observed that IAHC cells co-express αIIb, β3 and αv. Interestingly, αIIb, β3 and αv were mainly localized at the junction between the cells that form the IAHCs. Using this improved technique to immunostain viable PL slices, we were also able to observe the placental vasculature and groups of HSPCs expressing both αv and β3 in the vasculature of the chorionic plate. Similar to the IAHCs, αv and β3 were mainly at the junctions between the cells.

We have previously shown that hematopoietic progenitors in the E11 AGM and YS are CD41int, whereas they are in both CD41− and CD41int fractions in E12 PL and E14 FL (Robin et al., 2011). To test whether αIIb plays a role in the progenitor activity in the AGM, we examined a mouse line (αIIbtk/tk) in which the αIIb locus was disrupted by the integration of a tk gene, resulting in the lack of αIIb protein expression (Tronik-Le Roux et al., 2000). We observed no differences in the total number or types of progenitors in the AGM of E11 αIIb+/+, αIIb+/tk, or αIIbtk/tk embryos. Such results indicate that αIIb does not play a role in the regulation of the hematopoietic progenitors in the AGM region. This is in contrast to a study in which the disruption of αIIb results in an increased number of hematopoietic progenitors (CFU-Myeloid, BFU-E and CFU-Mk) in E9.5 YS, and in E12.5, E13.5 and E15.5 FL (Emambokus and Frampton, 2003). This difference in the requirement for αIIb on progenitors might depend on the resident microenvironment. Thus, αIIb does not play a functional role on the progenitors despite the fact that all progenitors express this marker in the AGM (Robin et al., 2011).

We observed fewer HSCs and a decrease in the HSC activity in the AGMs of αIIb mutant embryos. The few remaining HSCs were found to be functional in transplantation experiments, ruling out the possibility that αIIb mutant AGM HSCs are defective in homing to the adult BM niche. Interestingly, we did not find differences in the HSC activity in αIIb mutant YS and FL at the same time point of development (E11). The HSC activity was also normal at a later stage (E14), when HSC expansion occurs in the FL, indicating that αIIb mutant HSCs can undergo normal expansion. The HSC defect is thus restricted to the AGM region. The HSC activity was also lower after explant culture of the αIIb mutant AGMs showing that HSC activity is not maintained in the AGM when αIIb is absent. The defect seems to be cell intrinsic since only IAHC cells (where HSCs reside) express αIIb in the aorta at this stage of development. The observation that the HSC defect is similar in the AGMs in both αIIb+/tk and αIIbtk/tk embryos suggests that a certain threshold of αIIb on the surface of HSCs might therefore be necessary to maintain the HSC activity in the AGM.

We found in αIIb mutant embryos that the number of c-kit+ IAHC cells and the shape of the IAHCs are similar to that in wild-type embryos. Thus, either αIIb does not play a role in IAHC cell anchorage, or other adhesion molecules compensate for the absence of αIIb (e.g. αvβ3). The normal number of IAHCs also shows that αIIb, which is expressed by the emerging IAHCs and HSCs, is not required for the endothelial to hematopoietic transition (EHT).

Integrin binding to extra-cellular matrix compounds induces outside-in signaling through clustering of integrin heterodimers at focal adhesion sites (Gong et al., 2010; Hynes, 2002). This will recruit other cell surface receptors and many proteins that will activate intracellular signaling pathways. Therefore, the absence of αIIb might have direct or indirect consequences, resulting for example in the lack of recruitment of important receptors to the focal adhesion points (e.g. cytokine receptors) or the lack of signaling downstream of αIIbβ3 integrins. It was shown that platelet clot formation is mediated through phosphorylation of the c-Src kinase (regulating downstream effectors such as RhoA) after binding of αIIbβ3 to the Gα13 subunit (Gong et al., 2010). It was also recently shown that outside-in signaling via pY747 of β3 (β3PY747) following activation of αvβ3 integrin by TPO-mediated inside-out signaling is indispensable for TPO-mediated maintenance of HSC activity in vitro and in vivo within the BM niche (Umemoto et al., 2012). Whether such mechanisms are also active on E11 AGM HSCs will be the focus of further investigations.

Altogether our study shows that β3 and αv integrin subunits, in addition to αIIb, are reliable markers of the first HSCs found in the AGM. Such subunits are then differentially expressed by HSCs throughout embryonic development and can be used to isolate and localize HSCs. It has been shown that some integrin subunits are important for the retention of HSPCs in the adult BM niches (e.g. α4 (Scott et al., 2003)) and/or for the colonization of HSPCs into the FL and BM (e.g. β1 (Hirsch et al., 1996; Potocnik et al., 2000)). Here we highlight a new role for integrin subunits and provide evidence that αIIb is important to maintain the HSC activity in the aorta.

Acknowledgements

We thank Henk Dronk and Experimental Dieren Centrum (Erasmus MC) for mouse care. We thank Samly Srun and Daniëlle Seinstra for technical help at the beginning of the project; Dr Katrin Ottersbach, Dr Charles Durand and Anna Klaus for helpful discussions; and Dr Diana Tronik-Le Roux for giving us the authorization to use the αIIb+/tk mice that she generated. This work was supported by NWO (VIDI) grant 917-76-345 (C.R.), Landsteiner Foundation for Blood Transfusion Research (C.R.), NIH RO37DKKD54077 (E.D.), FES Netherlands Institute for Regenerative Medicine (E.D.) and ZonMW 91109036.

Footnotes

  • Competing interests The authors have no competing interests to declare.

  • Received November 22, 2012.
  • Accepted March 20, 2013.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Share Alike License (http://creativecommons.org/licenses/by-nc-sa/3.0/).

References

  1. ↵
    1. Boisset J. C.,
    2. Robin C.
    (2012). On the origin of hematopoietic stem cells: progress and controversy. Stem Cell Res. 8, 1–13. doi:10.1016/j.scr.2011.07.002
    OpenUrlPubMed
  2. ↵
    1. Boisset J. C.,
    2. van Cappellen W.,
    3. Andrieu–Soler C.,
    4. Galjart N.,
    5. Dzierzak E.,
    6. Robin C.
    (2010). In vivo imaging of haematopoietic cells emerging from the mouse aortic endothelium. Nature 464, 116–120. doi:10.1038/nature08764
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Boisset J. C.,
    2. Andrieu–Soler C.,
    3. van Cappellen W. A.,
    4. Clapes T.,
    5. Robin C.
    (2011). Ex vivo time-lapse confocal imaging of the mouse embryo aorta. Nat. Protoc. 6, 1792–1805. doi:10.1038/nprot.2011.401
    OpenUrlCrossRefPubMed
  4. ↵
    1. Bonig H.,
    2. Priestley G. V.,
    3. Wohlfahrt M.,
    4. Kiem H. P.,
    5. Papayannopoulou T.
    (2009a). Blockade of alpha6-integrin reveals diversity in homing patterns among human, baboon, and murine cells. Stem Cells Dev. 18, 839–844. doi:10.1089/scd.2008.0269
    OpenUrlCrossRefPubMed
  5. ↵
    1. Bonig H.,
    2. Watts K. L.,
    3. Chang K. H.,
    4. Kiem H. P.,
    5. Papayannopoulou T.
    (2009b). Concurrent blockade of alpha4-integrin and CXCR4 in hematopoietic stem/progenitor cell mobilization. Stem Cells 27, 836–837. doi:10.1002/stem.9
    OpenUrlCrossRefPubMed
  6. ↵
    1. Bouvard D.,
    2. Brakebusch C.,
    3. Gustafsson E.,
    4. Aszódi A.,
    5. Bengtsson T.,
    6. Berna A.,
    7. Fässler R.
    (2001). Functional consequences of integrin gene mutations in mice. Circ. Res. 89, 211–223. doi:10.1161/hh1501.094874
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Corbel C.,
    2. Salaün J.
    (2002). AlphaIIb integrin expression during development of the murine hemopoietic system. Dev. Biol. 243, 301–311. doi:10.1006/dbio.2001.0553
    OpenUrlCrossRefPubMed
  8. ↵
    1. Durand C.,
    2. Robin C.,
    3. Bollerot K.,
    4. Baron M. H.,
    5. Ottersbach K.,
    6. Dzierzak E.
    (2007). Embryonic stromal clones reveal developmental regulators of definitive hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 104, 20838–20843. doi:10.1073/pnas.0706923105
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Emambokus N. R.,
    2. Frampton J.
    (2003). The glycoprotein IIb molecule is expressed on early murine hematopoietic progenitors and regulates their numbers in sites of hematopoiesis. Immunity 19, 33–45. doi:10.1016/S1074-7613(03)00173-0
    OpenUrlCrossRefPubMed
  10. ↵
    1. Ferkowicz M. J.,
    2. Starr M.,
    3. Xie X.,
    4. Li W.,
    5. Johnson S. A.,
    6. Shelley W. C.,
    7. Morrison P. R.,
    8. Yoder M. C.
    (2003). CD41 expression defines the onset of primitive and definitive hematopoiesis in the murine embryo. Development 130, 4393–4403. doi:10.1242/dev.00632
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Gekas C.,
    2. Dieterlen–Lièvre F.,
    3. Orkin S. H.,
    4. Mikkola H. K.
    (2005). The placenta is a niche for hematopoietic stem cells. Dev. Cell 8, 365–375. doi:10.1016/j.devcel.2004.12.016
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Gong H.,
    2. Shen B.,
    3. Flevaris P.,
    4. Chow C.,
    5. Lam S. C.,
    6. Voyno–Yasenetskaya T. A.,
    7. Kozasa T.,
    8. Du X.
    (2010). G protein subunit Galpha13 binds to integrin alphaIIbbeta3 and mediates integrin “outside-in” signaling. Science 327, 340–343. doi:10.1126/science.1174779
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Grassinger J.,
    2. Haylock D. N.,
    3. Storan M. J.,
    4. Haines G. O.,
    5. Williams B.,
    6. Whitty G. A.,
    7. Vinson A. R.,
    8. Be C. L.,
    9. Li S.,
    10. Sørensen E. S.
    et al. (2009). Thrombin-cleaved osteopontin regulates hemopoietic stem and progenitor cell functions through interactions with alpha9beta1 and alpha4beta1 integrins. Blood 114, 49–59. doi:10.1182/blood-2009-01-197988
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Hirsch E.,
    2. Iglesias A.,
    3. Potocnik A. J.,
    4. Hartmann U.,
    5. Fässler R.
    (1996). Impaired migration but not differentiation of haematopoietic stem cells in the absence of beta1 integrins. Nature 380, 171–175. doi:10.1038/380171a0
    OpenUrlCrossRefPubMed
  15. ↵
    1. Hodivala–Dilke K. M.,
    2. McHugh K. P.,
    3. Tsakiris D. A.,
    4. Rayburn H.,
    5. Crowley D.,
    6. Ullman–Culleré M.,
    7. Ross F. P.,
    8. Coller B. S.,
    9. Teitelbaum S.,
    10. Hynes R. O.
    (1999). Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J. Clin. Invest. 103, 229–238. doi:10.1172/JCI5487
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Hynes R. O.
    (2002). Integrins: bidirectional, allosteric signaling machines. Cell 110, 673–687. doi:10.1016/S0092-8674(02)00971-6
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Lapidot T.,
    2. Dar A.,
    3. Kollet O.
    (2005). How do stem cells find their way home? Blood 106, 1901–1910. doi:10.1182/blood-2005-04-1417
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Matsubara A.,
    2. Iwama A.,
    3. Yamazaki S.,
    4. Furuta C.,
    5. Hirasawa R.,
    6. Morita Y.,
    7. Osawa M.,
    8. Motohashi T.,
    9. Eto K.,
    10. Ema H.
    et al. (2005). Endomucin, a CD34-like sialomucin, marks hematopoietic stem cells throughout development. J. Exp. Med. 202, 1483–1492. doi:10.1084/jem.20051325
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. McKinney–Freeman S. L.,
    2. Naveiras O.,
    3. Yates F.,
    4. Loewer S.,
    5. Philitas M.,
    6. Curran M.,
    7. Park P. J.,
    8. Daley G. Q.
    (2009). Surface antigen phenotypes of hematopoietic stem cells from embryos and murine embryonic stem cells. Blood 114, 268–278. doi:10.1182/blood-2008-12-193888
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Medvinsky A.,
    2. Dzierzak E.
    (1996). Definitive hematopoiesis is autonomously initiated by the AGM region. Cell 86, 897–906. doi:10.1016/S0092-8674(00)80165-8
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Mikkola H. K.,
    2. Fujiwara Y.,
    3. Schlaeger T. M.,
    4. Traver D.,
    5. Orkin S. H.
    (2003). Expression of CD41 marks the initiation of definitive hematopoiesis in the mouse embryo. Blood 101, 508–516. doi:10.1182/blood-2002-06-1699
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Mitjavila–Garcia M. T.,
    2. Cailleret M.,
    3. Godin I.,
    4. Nogueira M. M.,
    5. Cohen–Solal K.,
    6. Schiavon V.,
    7. Lecluse Y.,
    8. Le Pesteur F.,
    9. Lagrue A. H.,
    10. Vainchenker W.
    (2002). Expression of CD41 on hematopoietic progenitors derived from embryonic hematopoietic cells. Development 129, 2003–2013.
    OpenUrlPubMedWeb of Science
  23. ↵
    1. Müller A. M.,
    2. Medvinsky A.,
    3. Strouboulis J.,
    4. Grosveld F.,
    5. Dzierzak E.
    (1994). Development of hematopoietic stem cell activity in the mouse embryo. Immunity 1, 291–301. doi:10.1016/1074-7613(94)90081-7
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Notta F.,
    2. Doulatov S.,
    3. Laurenti E.,
    4. Poeppl A.,
    5. Jurisica I.,
    6. Dick J. E.
    (2011). Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science 333, 218–221. doi:10.1126/science.1201219
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Ottersbach K.,
    2. Dzierzak E.
    (2005). The murine placenta contains hematopoietic stem cells within the vascular labyrinth region. Dev. Cell 8, 377–387. doi:10.1016/j.devcel.2005.02.001
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Potocnik A. J.,
    2. Brakebusch C.,
    3. Fässler R.
    (2000). Fetal and adult hematopoietic stem cells require beta1 integrin function for colonizing fetal liver, spleen, and bone marrow. Immunity 12, 653–663. doi:10.1016/S1074-7613(00)80216-2
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. Prowse A. B.,
    2. Chong F.,
    3. Gray P. P.,
    4. Munro T. P.
    (2011). Stem cell integrins: implications for ex-vivo culture and cellular therapies. Stem Cell Res. 6, 1–12. doi:10.1016/j.scr.2010.09.005
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Qian H.,
    2. Tryggvason K.,
    3. Jacobsen S. E.,
    4. Ekblom M.
    (2006). Contribution of alpha6 integrins to hematopoietic stem and progenitor cell homing to bone marrow and collaboration with alpha4 integrins. Blood 107, 3503–3510. doi:10.1182/blood-2005-10-3932
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Rhodes K. E.,
    2. Gekas C.,
    3. Wang Y.,
    4. Lux C. T.,
    5. Francis C. S.,
    6. Chan D. N.,
    7. Conway S.,
    8. Orkin S. H.,
    9. Yoder M. C.,
    10. Mikkola H. K.
    (2008). The emergence of hematopoietic stem cells is initiated in the placental vasculature in the absence of circulation. Cell Stem Cell 2, 252–263. doi:10.1016/j.stem.2008.01.001
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    1. Robin C.,
    2. Durand C.
    (2010). The roles of BMP and IL-3 signaling pathways in the control of hematopoietic stem cells in the mouse embryo. Int. J. Dev. Biol. 54, 1189–1200. doi:10.1387/ijdb.093040cr
    OpenUrlCrossRefPubMed
  31. ↵
    1. Robin C.,
    2. Dzierzak E.
    (2005). Hematopoietic stem cell enrichment from the AGM region of the mouse embryo. Methods Mol. Med. 105, 257–272.
    OpenUrlPubMed
  32. ↵
    1. Robin C.,
    2. Ottersbach K.,
    3. Durand C.,
    4. Peeters M.,
    5. Vanes L.,
    6. Tybulewicz V.,
    7. Dzierzak E.
    (2006). An unexpected role for IL-3 in the embryonic development of hematopoietic stem cells. Dev. Cell 11, 171–180. doi:10.1016/j.devcel.2006.07.002
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Robin C.,
    2. Ottersbach K.,
    3. Boisset J. C.,
    4. Oziemlak A.,
    5. Dzierzak E.
    (2011). CD41 is developmentally regulated and differentially expressed on mouse hematopoietic stem cells. Blood 117, 5088–5091. doi:10.1182/blood-2011-01-329516
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Rybtsov S.,
    2. Sobiesiak M.,
    3. Taoudi S.,
    4. Souilhol C.,
    5. Senserrich J.,
    6. Liakhovitskaia A.,
    7. Ivanovs A.,
    8. Frampton J.,
    9. Zhao S.,
    10. Medvinsky A.
    (2011). Hierarchical organization and early hematopoietic specification of the developing HSC lineage in the AGM region. J. Exp. Med. 208, 1305–1315. doi:10.1084/jem.20102419
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Sánchez M. J.,
    2. Holmes A.,
    3. Miles C.,
    4. Dzierzak E.
    (1996). Characterization of the first definitive hematopoietic stem cells in the AGM and liver of the mouse embryo. Immunity 5, 513–525. doi:10.1016/S1074-7613(00)80267-8
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    1. Scott L. M.,
    2. Priestley G. V.,
    3. Papayannopoulou T.
    (2003). Deletion of alpha4 integrins from adult hematopoietic cells reveals roles in homeostasis, regeneration, and homing. Mol. Cell. Biol. 23, 9349–9360. doi:10.1128/MCB.23.24.9349-9360.2003
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Tronik–Le Roux D.,
    2. Roullot V.,
    3. Poujol C.,
    4. Kortulewski T.,
    5. Nurden P.,
    6. Marguerie G.
    (2000). Thrombasthenic mice generated by replacement of the integrin alphaIIb gene: demonstration that transcriptional activation of this megakaryocytic locus precedes lineage commitment. Blood 96, 1399–1408.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    1. Umemoto T.,
    2. Yamato M.,
    3. Shiratsuchi Y.,
    4. Terasawa M.,
    5. Yang J.,
    6. Nishida K.,
    7. Kobayashi Y.,
    8. Okano T.
    (2006). Expression of Integrin beta3 is correlated to the properties of quiescent hemopoietic stem cells possessing the side population phenotype. J. Immunol. 177, 7733–7739.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Umemoto T.,
    2. Yamato M.,
    3. Ishihara J.,
    4. Shiratsuchi Y.,
    5. Utsumi M.,
    6. Morita Y.,
    7. Tsukui H.,
    8. Terasawa M.,
    9. Shibata T.,
    10. Nishida K.
    et al. (2012). Integrin-αvβ3 regulates thrombopoietin-mediated maintenance of hematopoietic stem cells. Blood 119, 83–94. doi:10.1182/blood-2011-02-335430
    OpenUrlAbstract/FREE Full Text
  40. ↵
    1. Wagers A. J.,
    2. Weissman I. L.
    (2006). Differential expression of alpha2 integrin separates long-term and short-term reconstituting Lin−/loThy1.1loc-kit+ Sca-1+ hematopoietic stem cells. Stem Cells 24, 1087–1094. doi:10.1634/stemcells.2005-0396
    OpenUrlCrossRefPubMed
  41. ↵
    1. Yokomizo T.,
    2. Dzierzak E.
    (2010). Three-dimensional cartography of hematopoietic clusters in the vasculature of whole mouse embryos. Development 137, 3651–3661. doi:10.1242/dev.051094
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top

RSSRSS

Keywords

 Download PDF

Email
Research Article
Integrin αIIb (CD41) plays a role in the maintenance of hematopoietic stem cell activity in the mouse embryonic aorta
Jean-Charles Boisset, Thomas Clapes, Reinier Van Der Linden, Elaine Dzierzak, Catherine Robin
Biology Open 2013 2: 525-532; doi: 10.1242/bio.20133715
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
Citation Tools
Alerts

Article Navigation

Other journals from The Company of Biologists

Advertisement

Biology Open and COVID-19

We are aware that the COVID-19 pandemic is having an unprecedented impact on researchers worldwide. The Editors of all The Company of Biologists’ journals have been considering ways in which we can alleviate concerns that members of our community may have around publishing activities during this time. Read about the actions we are taking at this time.

Please don’t hesitate to contact the Editorial Office if you have any questions or concerns.

Future Leader Reviews launch in Biology Open

In the next phase of expanding our support for the early-career researcher community, we are launching Future Leader Reviews in Biology Open. Aimed at those in the first stages of their scientific career, they will provide an overview of a field of research from the perspective of biology's Future Leaders.

Find out more about about how to propose a Review.

Interview - Sonu Baral

Photo of Sonu

First author Sonu shares the story behind her latest BiO research, what this means for the field and where her science journey is heading to next.

Do you have an idea for a Workshop?

Our Workshop programme may be on hold for now, but we are welcoming ideas for the 2022 line-up. The proposal deadline is 29 May 2020, so find out how to pitch your idea to the Workshop Committee in good time.

How to promote your research

Three BiO covers

Publishing your paper is just the start of communicating your research to the world. Some researchers feel uneasy about self-promotion, but chances are your existing network is interested in what you’re doing – you just need to tell them! Sharing your work is useful and professional. Follow our 10 tips to get started.